Alfaxalone, a veterinary neurosteroid injectable intended for the induction and maintenance of anesthesia in dogs and cats, has been placed in Schedule IV (79 Fed. Reg. 10985; Feb. 27, 2014). Alfaxalone, previously spelled “alphaxalone,” has been marketed for years in Canada and Europe under the trade name Alfaxan (Abbott). The FDA approved U.S. marketing in October 2012 and recom... Read More